July 22, 2014Open Access

Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma

Key Points

Key points are not available for this paper at this time.

Abstract

Everolimus did not demonstrate noninferiority compared with sunitinib as a first-line therapy. The trial results support the standard treatment paradigm of first-line sunitinib followed by everolimus at progression.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Robert J. Motzer

Carlos H. Barrios

Tae Min Kim

Journals

Journal of Clinical Oncology

Actions

Institutions

Novartis (Switzerland)

University of Modena and Reggio Emilia

Novartis (United States)

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider